Clear All
11748 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50242-0142-01 50242-0142 Mosunetuzumab Lunsumio 30.0 mg/30mL Immunotherapy Monoclonal Antibody CD20, CD3 Intravenous Dec 22, 2022 In Use
50242-0159-01 50242-0159 Mosunetuzumab Lunsumio 1.0 mg/mL Immunotherapy Monoclonal Antibody CD20, CD3 Intravenous Dec 22, 2022 In Use
70383-0073-01 70383-0073 MOTIXAFORTIDE ACETATE Aphexda 62.0 mg/1.7mL Ancillary Therapy Immunostimulant Stem cell mobilizer Subcutaneous Sep 8, 2023 In Use
82737-0073-01 82737-0073 Motixafortide Aphexda 62.0 mg/1.7mL Ancillary Therapy Immunostimulant Stem cell mobilizer Subcutaneous Sep 8, 2023 In Use
73441-0062-01 73441-0062 MOTIXAFORTIDE APHEXDA 62.0 mg/1.7mL Ancillary Therapy Immunostimulant Stem cell mobilizer Subcutaneous Jun 15, 2025 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
00310-4700-01 00310-4700 moxetumomab pasudotox LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Oct 24, 2018 Sep 30, 2024 No Longer Used
00187-1221-03 00187-1221 Nabilone Cesamet 1.0 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral Nov 1, 2009 Nov 13, 2017 No Longer Used
00187-1231-50 00187-1231 Nabilone Cesamet 1.0 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral Mar 9, 2020 In Use
00037-1221-50 00037-1221 Nabilone Cesamet 1.0 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral Mar 1, 2010 Mar 31, 2020 No Longer Used
55566-1050-01 55566-1050 Nadofaragene firadenovec-vncg ADSTILADRIN 300000000000.0 {VP}/mL Immunotherapy Gene Therapy IFN⍺2b Intravesical Jul 1, 2023 In Use
73042-0201-01 73042-0201 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Nov 25, 2020 In Use
00002-7716-01 00002-7716 Necitumumab Portrazza 16.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Nov 24, 2015 In Use
80978-0111-06 80978-0111 Nelarabine injection NELARABINE 250.0 mg/50mL Chemotherapy Antimetabolite Purine Analog Intravenous Apr 12, 2023 In Use
46708-0813-63 46708-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug 1, 2024 In Use
39822-0650-01 39822-0650 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Feb 17, 2025 In Use
72205-0154-04 72205-0154 NELARABINE NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct 22, 2024 In Use
71288-0165-53 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan 10, 2023 Jan 2, 2025 In Use
62332-0813-50 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug 1, 2024 In Use
70771-1685-08 70771-1685 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov 17, 2021 In Use
81927-0111-01 81927-0111 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Mar 15, 2023 In Use
70771-1685-01 70771-1685 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov 17, 2021 In Use
62332-0813-63 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug 1, 2024 In Use
70710-1726-08 70710-1726 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov 17, 2021 In Use
43598-0142-06 43598-0142 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan 9, 2023 In Use

Found 11748 results — Export these results